Join the Perseris group to help and get support from people like you.
Perseris News
Weekly LYN-005 Provides Sustained Risperidone Release in Schizophrenia
WEDNESDAY, June 18, 2025 – For patients with schizophrenia, weekly LYN-005 provides sustained release of risperidone at therapeutic concentrations, according to a study published online June 11 in...
Innovative Once-Weekly Risperidone Capsule Helps Quell Schizophrenia Symptoms
MONDAY, June 16, 2025 — A new breakthrough can help people with schizophrenia keep up with their psychiatric meds, researchers said. A pill taken just once a week, gradually releasing medicine from w...
FDA Approves Perseris (risperidone) for Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
SLOUGH, England and RICHMOND, Va., July 27, 2018 /PRNewswire/ – Indivior PLC (LON: INDV) today announced that the U.S. Food and Drug Administration (FDA) has approved Perseris, the first...